JP2022530442A5 - - Google Patents

Info

Publication number
JP2022530442A5
JP2022530442A5 JP2021563165A JP2021563165A JP2022530442A5 JP 2022530442 A5 JP2022530442 A5 JP 2022530442A5 JP 2021563165 A JP2021563165 A JP 2021563165A JP 2021563165 A JP2021563165 A JP 2021563165A JP 2022530442 A5 JP2022530442 A5 JP 2022530442A5
Authority
JP
Japan
Prior art keywords
antibody
amino acid
seq
adc
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021563165A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022530442A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/029656 external-priority patent/WO2020219774A1/en
Publication of JP2022530442A publication Critical patent/JP2022530442A/ja
Publication of JP2022530442A5 publication Critical patent/JP2022530442A5/ja
Withdrawn legal-status Critical Current

Links

JP2021563165A 2019-04-24 2020-04-23 アントラサイクリン抗体薬物複合体およびその使用 Withdrawn JP2022530442A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962838267P 2019-04-24 2019-04-24
US62/838,267 2019-04-24
PCT/US2020/029656 WO2020219774A1 (en) 2019-04-24 2020-04-23 Anthracycline antibody-drug conjugates and uses thereof

Publications (2)

Publication Number Publication Date
JP2022530442A JP2022530442A (ja) 2022-06-29
JP2022530442A5 true JP2022530442A5 (enExample) 2023-05-01

Family

ID=72940981

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021563165A Withdrawn JP2022530442A (ja) 2019-04-24 2020-04-23 アントラサイクリン抗体薬物複合体およびその使用

Country Status (4)

Country Link
US (1) US20220226493A1 (enExample)
EP (1) EP3959242A4 (enExample)
JP (1) JP2022530442A (enExample)
WO (1) WO2020219774A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019084057A2 (en) 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS
AU2019265019B2 (en) 2018-05-11 2025-11-06 Beam Therapeutics Inc. Methods of substituting pathogenic amino acids using programmable base editor systems
AU2019366960A1 (en) * 2018-10-23 2021-05-27 Regeneron Pharmaceuticals, Inc. Fc silenced antibody drug conjugates (ADCs) and uses thereof
CN120399078B (zh) * 2025-05-08 2026-03-06 上海天泽云泰生物医药股份有限公司 靶向cd117的纳米抗体及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214786B2 (en) * 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
SG128680A1 (en) * 2003-07-22 2007-01-30 Crucell Holland Bv Binding molecules against sars-coronavirus and uses thereof
US8722587B2 (en) * 2008-04-09 2014-05-13 The Trustees Of The University Of Pennsylvania Single chain fragment variable antibody libraries and uses thereof
CA2742969A1 (en) * 2008-11-07 2010-05-14 Fabrus Llc Anti-dll4 antibodies and uses thereof
AR086044A1 (es) * 2011-05-12 2013-11-13 Imclone Llc Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos
RU2017120361A (ru) * 2014-11-10 2018-12-13 Ф.Хоффманн-Ля Рош Аг Антитела к pdgf-b и способы их применения
HK1256681A1 (zh) * 2015-04-06 2019-10-04 President And Fellows Of Harvard College 用於非清髓性预处理的组合物和方法
EP3356415B1 (en) * 2015-09-29 2024-05-01 Amgen Inc. Asgr inhibitors for reduzing cholesterol levels
BR112018074453A2 (pt) * 2016-05-27 2019-03-19 Abbvie Biotherapeutics Inc. proteínas de ligação biespecíficas ligando uma protéina imunomoduladora e um antígeno tumoral
IL263744B2 (en) * 2016-06-17 2023-11-01 Magenta Therapeutics Inc Compositions and methods for the depletion of cd117 plus cells
KR20200069364A (ko) * 2017-10-24 2020-06-16 마젠타 테라퓨틱스 인코포레이티드 Cd117+ 세포의 고갈을 위한 조성물 및 방법
WO2019084057A2 (en) * 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS
WO2019084053A1 (en) * 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS
WO2019084067A1 (en) * 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. ANTI-CD117 ANTIBODIES AND METHODS OF USE
JP2021526525A (ja) * 2018-06-07 2021-10-07 マジェンタ セラピューティクス インコーポレイテッドＭａｇｅｎｔａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 抗体薬物コンジュゲート（ａｄｃｓ）を用いた治療方法
AU2019366960A1 (en) * 2018-10-23 2021-05-27 Regeneron Pharmaceuticals, Inc. Fc silenced antibody drug conjugates (ADCs) and uses thereof
WO2020092655A1 (en) * 2018-10-30 2020-05-07 Magenta Therapeutics, Inc. Methods for allogeneic hematopoietic stem cell transplantation
EP3958909A4 (en) * 2019-04-24 2024-01-10 Magenta Therapeutics, Inc. ANTI-CD117 ANTIBODY DRUG CONJUGATES AND USES THEREOF
EP3958902A4 (en) * 2019-04-24 2023-01-25 Magenta Therapeutics, Inc. ANTI-CD117 ANTIBODIES AND THEIR USES
JP2022530443A (ja) * 2019-04-24 2022-06-29 マジェンタ セラピューティクス インコーポレイテッド 抗ｃｄ１１７抗体薬物複合体およびその使用

Similar Documents

Publication Publication Date Title
JP2022530442A5 (enExample)
JP2022530438A5 (enExample)
EP4494657A1 (en) Exatecan derivative-antibody conjugate and medical use thereof
DE69626849T2 (de) Verzweigte hydrazongruppen enthaltende kuppler
JP2022512778A5 (enExample)
US12311030B2 (en) Antibody-sting agonist conjugates and their use in immunotherapy
JP5314590B2 (ja) カンプトテシン結合部分
CN107074879B (zh) 应用于细胞结合分子-药物共轭体的新型细胞毒性分子
JP2022530089A5 (enExample)
RU2004135101A (ru) Коньюгаты "производные калихеамицина-носитель"
WO2019170131A1 (zh) 靶向cd73的抗体及抗体-药物偶联物、其制备方法和用途
EP3335734A1 (en) Linker-drug and antibody-drug conjugate (adc) employing the same
UA119167C2 (uk) Біспецифічне антитіло, яке зв'язується з cd38 та cd3
HUE035463T2 (hu) Citotoxikus peptidek és ezek antitest-hatóanyag konjugátumai
IE76467B1 (en) New linker for bioactive agents
JP2009506790A (ja) 毒素とコンジュゲートしたｅｐｈ受容体抗体
EP3165237A1 (en) Antibody-drug conjugate (adc) and method for forming the same
JP2025518739A (ja) オリゴ糖リンカー、オリゴ糖リンカーを含むリンカー－ペイロード、および糖鎖がリモデリングされた抗体薬物複合体、その製造方法と使用
JP2024506590A (ja) リンカー－ペイロードおよびそのコンジュゲート
HU218093B (hu) Rák kezelésére alkalmazható, nagy affinitású, módosított antitestek új csoportja, eljárás előállítására, valamint az antitesteket tartalmazó konjugátumok és készítmények
TWI905962B (zh) 用於綴合之化合物、綴合物及包含其之醫藥組成物
CN107583058A (zh) 一种t‑2毒素‑抗体缀合物及其用途
RU2005101621A (ru) Антитела и их применения
EP4442283A1 (en) Anti-human trop2 antibody-camptothecin drug conjugate and medical use thereof
KR102835630B1 (ko) 신규 항체 약물 접합체